RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Brainstorm Cell Therapeutics Stock

Brainstorm Cell Therapeutics EBIT 2024

Brainstorm Cell Therapeutics EBIT

-12.2 M USD

Ticker

BCLI

ISIN

US10501E2019

WKN

A12BXW

In 2024, Brainstorm Cell Therapeutics's EBIT was -12.2 M USD, a -43.09% increase from the -21.44 M USD EBIT recorded in the previous year.

The Brainstorm Cell Therapeutics EBIT history

YEAREBIT (undefined USD)
2030e575.37
2029e331.54
2028e196.65
2027e86.31
2026e-25.83
2025e-21.28
2024e-12.2
2023-21.44
2022-24.82
2021-24.54
2020-31.68
2019-23
2018-14.06
2017-5
2016-5.08
2015-8.54
2014-7.42
2013-5.04
2012-3.52
2011-3.89
2010-2.59
2009-1.75
2008-3.27
2007-4.92
2006-2.88
2005-2.57

Brainstorm Cell Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Brainstorm Cell Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Brainstorm Cell Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Brainstorm Cell Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Brainstorm Cell Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Brainstorm Cell Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Brainstorm Cell Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Brainstorm Cell Therapeutics’s growth potential.

Brainstorm Cell Therapeutics Revenue, EBIT and net profit per share

DateBrainstorm Cell Therapeutics RevenueBrainstorm Cell Therapeutics EBITBrainstorm Cell Therapeutics Net Income
2030e1.26 B undefined575.37 M undefined556.03 M undefined
2029e755.18 M undefined331.54 M undefined839.31 M undefined
2028e433.25 M undefined196.65 M undefined213.89 M undefined
2027e227.35 M undefined86.31 M undefined118.51 M undefined
2026e0 undefined-25.83 M undefined-16.23 M undefined
2025e0 undefined-21.28 M undefined-17.05 M undefined
2024e0 undefined-12.2 M undefined-11.77 M undefined
20230 undefined-21.44 M undefined-17.19 M undefined
20220 undefined-24.82 M undefined-24.28 M undefined
20210 undefined-24.54 M undefined-24.46 M undefined
20200 undefined-31.68 M undefined-31.81 M undefined
20190 undefined-23 M undefined-23.25 M undefined
20180 undefined-14.06 M undefined-13.95 M undefined
20170 undefined-5 M undefined-4.95 M undefined
20160 undefined-5.08 M undefined-4.98 M undefined
20150 undefined-8.54 M undefined-8.49 M undefined
20140 undefined-7.42 M undefined-9.25 M undefined
20130 undefined-5.04 M undefined-4.9 M undefined
20120 undefined-3.52 M undefined-3.43 M undefined
20110 undefined-3.89 M undefined-3.92 M undefined
20100 undefined-2.59 M undefined-2.42 M undefined
20090 undefined-1.75 M undefined-1.78 M undefined
20080 undefined-3.27 M undefined-3.47 M undefined
20070 undefined-4.92 M undefined-6.24 M undefined
20060 undefined-2.88 M undefined-3.92 M undefined
20050 undefined-2.57 M undefined-2.6 M undefined

Brainstorm Cell Therapeutics stock margins

The Brainstorm Cell Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Brainstorm Cell Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Brainstorm Cell Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Brainstorm Cell Therapeutics's sales revenue. A higher gross margin percentage indicates that the Brainstorm Cell Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Brainstorm Cell Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Brainstorm Cell Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Brainstorm Cell Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Brainstorm Cell Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Brainstorm Cell Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Brainstorm Cell Therapeutics Margin History

Brainstorm Cell Therapeutics Gross marginBrainstorm Cell Therapeutics Profit marginBrainstorm Cell Therapeutics EBIT marginBrainstorm Cell Therapeutics Profit margin
2030e0 %45.85 %44.3 %
2029e0 %43.9 %111.14 %
2028e0 %45.39 %49.37 %
2027e0 %37.96 %52.13 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %
20060 %0 %0 %
20050 %0 %0 %

Brainstorm Cell Therapeutics Aktienanalyse

What does Brainstorm Cell Therapeutics do?

Brainstorm Cell Therapeutics Inc is an emerging biotech company based in New York City that focuses on developing novel therapies for the treatment of neurodegenerative diseases. The company was founded in 2002 by a team of leading scientists and experts in the field of stem cell research. Their goal was to advance the development of treatment options for diseases such as ALS (Amyotrophic Lateral Sclerosis), Multiple Sclerosis, and Parkinson's through innovative approaches to stem cell therapy. Brainstorm Cell Therapeutics' business model is based on the unique property of stem cells to differentiate into a variety of cell types and regenerate damaged tissue. The company harnesses this ability to develop tailored stem cell therapies that are customized to meet the specific needs of each patient. By utilizing the potential of stem cells to repair tissue damage and support the body's own healing process. The company is divided into two divisions: therapeutics and diagnostics. The therapeutics division is the core area, focusing on the development of stem cell therapies for the treatment of ALS, Multiple Sclerosis, Parkinson's, and other diseases. The company has developed an approach using autologous stem cells, where stem cells are extracted from the patient's own body to minimize the risk of rejection reactions. The company has already reached Phase II clinical trials and has demonstrated promising results from this innovative technology stem cell therapy for the treatment of ALS, as well as MS and Parkinson's. The diagnostics division of Brainstorm Cell Therapeutics focuses on the development of diagnostic tests to aid physicians in diagnosing patients with neurodegenerative diseases more quickly and accurately. One of the current developments is the NurOwn ALS diagnostic test, which is based on the impact of ALS on the patient's immune system. One of Brainstorm Cell Therapeutics' most well-known products is "NurOwn." This stem cell therapy product is provided to ALS patients. The product utilizes the patient's autologous stem cells to slow the progression of the disease and promote the growth of healthy tissue. It is a personalized therapy, tailored to the specific needs of each patient. The company has already conducted various clinical trials with NurOwn and achieved promising results. Brainstorm Cell Therapeutics is an innovative biotech company focused on the development of stem cell therapies for the treatment of neurodegenerative diseases. The company has already achieved promising results with its therapies and plans to further improve its product range. With a strong scientific team and innovative business model, it is well-positioned to play a leading role in the development of therapies for the treatment of neurodegeneration in the future. Brainstorm Cell Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Brainstorm Cell Therapeutics's EBIT

Brainstorm Cell Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Brainstorm Cell Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Brainstorm Cell Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Brainstorm Cell Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Brainstorm Cell Therapeutics stock

How much did Brainstorm Cell Therapeutics achieve in EBIT for the current year?

In the current year, Brainstorm Cell Therapeutics has achieved an EBIT of -12.2 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Brainstorm Cell Therapeutics.

How has the EBIT of Brainstorm Cell Therapeutics developed in recent years?

The EBIT of Brainstorm Cell Therapeutics has increased by -43.092% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Brainstorm Cell Therapeutics?

The EBIT of Brainstorm Cell Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Brainstorm Cell Therapeutics pay?

Over the past 12 months, Brainstorm Cell Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Brainstorm Cell Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Brainstorm Cell Therapeutics?

The current dividend yield of Brainstorm Cell Therapeutics is .

When does Brainstorm Cell Therapeutics pay dividends?

Brainstorm Cell Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Brainstorm Cell Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Brainstorm Cell Therapeutics located?

Brainstorm Cell Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Brainstorm Cell Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Brainstorm Cell Therapeutics from 8/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/17/2024.

When did Brainstorm Cell Therapeutics pay the last dividend?

The last dividend was paid out on 8/17/2024.

What was the dividend of Brainstorm Cell Therapeutics in the year 2023?

In the year 2023, Brainstorm Cell Therapeutics distributed 0 USD as dividends.

In which currency does Brainstorm Cell Therapeutics pay out the dividend?

The dividends of Brainstorm Cell Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Brainstorm Cell Therapeutics

Our stock analysis for Brainstorm Cell Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Brainstorm Cell Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.